Singapore's Novena Global Lifecare, through its subsidiary Novena Life Sciences, increased its stake in Hexin Health Corporation, Taiwan, China's 3rd largest health screening provider, from 20% to 50.1% and acquired 50.1% of Bolian Biotech and Lianwei Bio